Chronic Lymphocytic Leukemia Drug Treatment Shows Promise 
LiveScience.com
An experimental drug, called ibrutinib, shows promise treating elderly patients with chronic lymphocytic leukemia, according to preliminary findings from a phase I/II clinical trial. Clinical trial results do not always hold up in later studies.
Kinder Drugs for Seniors dailyRx

all 5 news articles » 

Blood Matters: For the 17th Year, Thousands of Hematologists Meet in Amsterdam ... 
MarketWatch (press release)
Dr Topp - Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in patients with refractory disease. Dr Ramsy - How malignant cells in patients with Chronic Lymphocytic Leukemia escape the deadly T-cell attack.

and more » 

Experimental agent may help older people with chronic leukemia 
EurekAlert (press release)
This agent merits further testing as a first-line therapy for older chronic-leukemia patients. COLUMBUS, Ohio ? The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia ...
Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib ... MarketWatch (press release)

all 24 news articles » 

Identifying Aggressive Leukemia 
dailyRx
There are two main types of chronic lymphocytic leukemia, and knowing whether a patient has the aggressive or the slow version is very important to determine treatment early on. New research from the University of California-San Diego School of ...

and more » 

STAT3 Mutations Linked to Rare Leukemia 
MedPage Today
The patients with these mutations were more likely to have neutropenia and rheumatoid arthritis than other large granular lymphocytic leukemia patients without STAT3 gene mutations. Mutations in the STAT3 gene are common in patients with large granular ...
STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder Doctors Lounge

all 4 news articles » 

Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete ... 
MarketWatch (press release)
Blinatumomab is the first of the BiTE antibodies and Amgen has received orphan drug designation from the US Food and Drug Administration for the treatment of ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia and ...
Amgen: AMG 103 Phase 2 Data Shows High CR Rate In Leukemia Patients NASDAQ

all 40 news articles » 

/C O R R E C T I O N -- Amgen/ 
MarketWatch (press release)
Blinatumomab is the first of the BiTE antibodies and Amgen has received orphan drug designation from the US Food and Drug Administration for the treatment of ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia and ...
Amgen Presents Oncology Data Zacks.com

all 11 news articles » 

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment ... 
MarketWatch (press release)
GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being evaluated in combination with rituximab in previously treated chronic lymphocytic leukemia (CLL) patients.

and more » 

Gilead initiates Phase III chronic lymphocytic leukemia trial 
Pharmaceutical Business Review
Gilead Sciences has announced the dosing of first patient in a Phase III clinical trial evaluating GS-1101 (formerly CAL-101) for the treatment of chronic lymphocytic leukemia (CLL). The Study 116, a randomized, double-blind study, will enroll 160 ...

and more » 

Donate your empties to fight leukemia 
insideTORONTO.com
"I am facing a new battle now, alongside thousands of other Canadians - leukemia." Henderson was diagnosed with chronic lymphocytic leukemia (CLL) in November 2009. CLL is the leading type of leukemia diagnosed in Canadian adults.

and more »